Tirapazamine cytotoxicity for neuroblastoma is p53 dependent

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2774-2780

  Yang, Bo ^a,b   Reynolds, C Patrick ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CASPASE INHIBITOR; GLUTATHIONE; PROTEIN P21; PROTEIN P53; TERT BUTYLOXYCARBONYL DEXTRO FLUOROMETHYL KETONE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BENZYL COMPOUNDS; BLOTTING, WESTERN; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; HYDROCARBONS, FLUORINATED; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MITOCHONDRIA; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRIAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17644416399     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2382     Document Type: Article

References (54)

1. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 1993;12:73-82.
2. Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 2000;82:651-6.
3. Evans JW, Yudoh K, DelahoussayeYM, Brown JM. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 1998;58:2098-101.
4. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48:791-5.
5. Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 1998;13:541-73.
6. Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia 1999;1:461-7.
7. Clement JJ, Gorman MS, Wodinsky I, Catane R, Johnson RK. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res 1980;40:4165-72.
8. Goldberg Z, Evans J, Birrell G, Brown JM. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. Int J Radiat Oncol Biol Phys 2001;49:175-82.
9. Masunaga S, Ono K, Hori H, et al. Change in oxygenation status in intratumour total and quiescent cells following γ-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment. Br J Radiol 2000;73:978-86.
10. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000;60:3761-9.
11. Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 1999;10 Suppl 5:S29-33.
12. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999;80:1245-51.
13. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48:791-5.
14. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
15. Reynolds CP, Seeger RC. Neuroblastoma. In Haskell CM, editors. Cancer Treatment, 5th ed. Philadelphia: W.B. Saunders; 2000. p. 1214-36.
16. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
17. Grant JL, Smith B. Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man. Ann Intern Med 1963;58:801-9.
18. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol 1993;11:2226-33.
19. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res 2001;61:5103-5.
20. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003;63:1520-6.
21. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649-60.
22. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study [see comments]. J Natl Cancer Inst 1991;83:178-85.
23. Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 1999;10 Suppl 5:S29-33.
24. Nagasawa H, Yamashita M, Mikamo N, et al. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Comp Biochem Physiol A Mol Integr Physiol 2002;132:33-40.
25. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405.
26. Reynolds CP, Biedler JL, Spengler BA, et al. Characterization of human neuroblastoma cell lines established before end after therapy. J Natl Cancer Inst 1986;76:375-87.
27. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
28. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized 02 tension measurements. Cancer Res 1991;51:3316-22.
29. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 1996;24:204-13.
30. Chou J, Chou TC. Dose effect analysis with microcomputers. Dose Effect Analysis with Microcomputers. Cambridge, UK: Elsevier-Biosoft; 1988.
31. 2 in cultured endothelial cells. Arch Biochem Biophys 1993;302:348-55.
32. Vandeputte C, Guizon I, Genestie-Denis I, Vannier B, Lorenzon G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol Toxicol 1994;10:415-21.
33. Butturini A, Chen RL, Tang SQ, et al. Detection of bone marrow metastases in neuroblastoma by RT-PCR for neural and tumor associated genes. Proc Amer Soc Clin Oncol 1996;15:468.
34. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61:4864-72.
35. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998;1366:151-65.
36. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 1997;138:449-69.
37. Shulman LN, Buswell L, Riese N, et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 1999;44:349-53.
38. Anderson CP, Tsai JM, Meek WE, et al. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999;246:183-92.
39. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909.
40. Brown JM. SR 4233 (tirapazamine): a new anti-cancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993;67:1163-70.
41. Hartwell LH, Kastan MB. Cell Cycle control and cancer. Science 1994;266:1821-8.
42. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncot 2002;29:246-57.
43. Hall AG. Review: The role of glutathione in the regulation of apoptosis. Eur J Clin Invest 1999;29:238-45.
44. Kondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 2001;276:12076-83.
45. Serafino A, Sinibaldi-Vallebona P, Lazzarino G, et al. Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis. Anticancer Res 2000;20:3383-94.
46. Wilson MR. Apoptotic signal transduction: emerging pathways. Biochem Cell Biol 1998;76:573-82.
47. Yang CF, Shen HM, Ong CN. Intracellular thiol depletion causes mitochondrial permeability transition in ebselen-induced apoptosis. Arch Biochem Biophys 2000;380:319-30.
48. Zou H, Li Y, Liu X, Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
49. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
50. Tew KD, Houghton RJ, Houghton JA. Preclinical and clinical modulation of anticancer drugs. Preclinical and Clinical Modulation of Anticancer Drugs, Boca Raton: CRC Press: 1993. p. 13-7.
51. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29:684-8.
52. Brady HJ, Gil-Gomez G. Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 1998;30:647-50.
53. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28-37.
54. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A 1996;93:11848-52.